- Published at
- by investing.com
positive
positive
NVNO Stock Hits 52-Week Low at $3.06 Amid Market Challenges By Investing.com
NVNO Stock Hits 52-Week Low at $3.06 Amid Market Challenges
News for Hancock Jaffe Laboratories, Inc. (HJLI)
- Published at
- by seekingalpha.com
negativenegativeenVVeno Medical (NVNO) Stock: Unique Exposure To Venous Treatment Domain
enVVeno Medical continues to advance its key product pipeline through two clinical trials. The two latest clinical trials have garnered investor's attention. Read here for the stock outlook.- Published at
- by etfdailynews.com
mixedmixedEquities Research Analysts’ Upgrades for May 27th (AAWW, AN, ATDRY, ATO, AUTO, BOOT, BSX, DML, DNN, DXC)
Read Equities Research Analysts’ Upgrades for May 27th (AAWW, AN, ATDRY, ATO, AUTO, BOOT, BSX, DML, DNN, DXC) at ETF Daily News- Published at
- by etfdailynews.com
mixedmixedZacks Investment Research Upgrades enVVeno Medical (NASDAQ:NVNO) to Hold
Read Zacks Investment Research Upgrades enVVeno Medical (NASDAQ:NVNO) to Hold at ETF Daily News- Published at
- by etfdailynews.com
mixedmixedInvestment Analysts’ Upgrades for May 7th (BLRX, CDZI, CTO, DMLP, GABC, HA, HIFS, HSY, KMT, KZIA)
Read Investment Analysts’ Upgrades for May 7th (BLRX, CDZI, CTO, DMLP, GABC, HA, HIFS, HSY, KMT, KZIA) at ETF Daily NewsWYNMYWYNMFWITN.MXWITWIPRO.NSWIPRO.BOVVNTVRNAVECTUSXUSPHUBATGLSSRZNSLQTSITEREXRRDWPRVBNEXA.TONEXALVS.MXLVS.BALVSLV2B.DELEVI.MXLEVILCR.DEL1VS34.SACDZIBLRX.TABLRX1128.HK0QY4.LVITLUMHUFABTWITOMZTCPCTASEKEYSEKEFSCHYYSCHYFRWNFFRWEOYRWEN.MXRWEA.DERWE.PRRWE.MIRWE.DERNSDFRNO.PARNO.MIRNLSYRNL.DERCKYOGN.MXOGN-WINEUMNKDMECMATXLSEAWLSEALSCCLFSYYLFSYFKZIAKZA.AXHJLIWHJLIHJLBWHIFSGNPK-WTGNPK-UNGNPKGLEO-UNGLEOGABCCHFW-WTCHFW-UNCHFW6724.T1928.HK1212.HKPRTSKMT- Published at
- by etfdailynews.com
mixedmixedenVVeno Medical (NASDAQ:NVNO) Rating Increased to Hold at Zacks Investment Research
Read enVVeno Medical (NASDAQ:NVNO) Rating Increased to Hold at Zacks Investment Research at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveenVVeno Medical (NASDAQ:NVNO) Downgraded to “Sell” at Zacks Investment Research
Read enVVeno Medical (NASDAQ:NVNO) Downgraded to “Sell” at Zacks Investment Research at ETF Daily News- Published at
- by prnewswire.com
neutralneutralWorldwide Bioprosthetics Industry to 2026 - Compatibility Issues With Synthetic or Mechanical Implants Presents Opportunities
/PRNewswire/ -- The "Bioprosthetics Market Research Report by Type, Application, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report...- Published at
- by marketscreener.com
neutralneutralHancock Jaffe Laboratories : NVNO Corporate Presentation
Setting New Standards for Venous Care October 2021 Investor Presentation ... | October 14, 2021- Published at
- by marketscreener.com
neutralneutralHancock Jaffe Laboratories : NVNO Presentation October
Setting New Standards for Venous Care October 2021 Investor Presentation Nasdaq: NVNO enVVeno.com ... | October 13, 2021- Published at
- by marketscreener.com
neutralneutralHancock Jaffe Laboratories : CERTIFICATE OF AMENDMENT TO THE FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HANCOCK JAFFE LABORATORIES, INC (Form 8-K)
CERTIFICATE OF AMENDMENT TO THE FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HANCOCK JAFFE LABORATORIES, INC. The undersigned, for... | October 1, 2021- Published at
- by marketscreener.com
positivepositiveHancock Jaffe Laboratories : to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann Download as PDFSeptember 24, 2021 Live webinar followed by... | September 24, 2021- Published at
- by marketscreener.com
positivepositiveHancock Jaffe Laboratories : Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs
September 21, 2021 Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs ... | September 21, 2021- Published at
- by markets.businessinsider.com
mixedmixed75 Biggest Movers From Yesterday
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares climbed 68.1% to close at $58.25 on Tuesday after the company announced that th...YOUXELAWXELAUXELAWHLRPWHLRDWHLRWHLMTBIOTASEDGN.MXSEDGRMEDPALTOTLKNEWTLNEWTMYGNMYD.DEMRNA.MXMRNAMOXCMOHOMIROMETCM1RN34.SALVTXITHOLIHLITHJLIWHJLIHJLBWG1AR34.SAFTRPFFTRP.TOFTRP.CNFHSEVKEVERDVDDSKEWDSKEDLPNCEMIBPN.MXBPE5.DEBPE.DEBPAQFBP.LBP-B.LBP-A.LBPB1PP34.SAAUTOATKR.MXATKRATIPARCTAPDNAHPIACYABVC0M58.L0L7S.L0K7X.L0K3W.L0J38.L0ITV.L0HKP.L0A45.LZGY.DEXBIOWXBIOWWDUTIUCTTUANTRKATKATSTIMSPNESEEDRNAOSATNTESN.MXNTES.BANTESNTECNETTFMAXLHDXKOPNKNSAIVACIPGP.MXIPGPIIIFLGCFIS.MXFISF1NI34.SADZSI9999.HK0LID.L0JRR.L0J86.L0ILW.LSPRTSJOYWSJSIBNSAVA.MXSAVALDICXX.DECLXC34.SACLX.MXCLXBHGBHCN.MXBHC.TOBHC0I0J.L- Published at
- by thestockmarketwatch.com
mixedmixedStocks of Note for Feb-9 Morning
EVINE Live Inc is a multiplatform video commerce company that offers a mix of proprietary, exclusive and name brands directly to consumers in an engaging and in...- Published at
- by rttnews.com
mixedmixedATHE Gets Funds For Parkinson's Research, No Safety Issues For QURE's Trial, TNXP On Watch
Today's Daily Dose brings you news about Alterity securing funds for Parkinson's research, the Independent Data Monitoring Committee recommending ERYTECH's pancreatic cancer trial to continue, Ocugen's $23 million registered direct offering, uniQure's Huntington's disease trial, and Tonix Pharma's proposed diagnostic skin test to measure T cell immunity to SARS-CoV-2.- Published at
- by markets.businessinsider.com
mixedmixed45 Stocks Moving in Wednesday's Pre-Market Session
Gainers Summit Midstream Partners, LP (NYSE:SMLP) shares rose 58.3% to $21.67 in pre-market trading after the company reported achievement of ke...ZGV3.MUZGV3.FZGV3.BEXELAWXELATPMR.MUTPMR.FTPMR.BETNXPTMBRSTIMSMLPNRC.SGNRC.MUNRC.FNDM.TOND3.SGND3.MUND3.FND3.BENCNANAKN04A.SGN04A.FN04A.BEMTRXJAGXIBIOHJLIGEVOFLNTET82.SGET82.MUET82.FET82.DUET82.BEDYNTCTRMBPC2.FAIRIAEZS.TOAEZS7TM.F1JA2.SG1JA2.F1JA2.BE1C1.MU1C1.F1C1.DU1C1.BE0JVN.MU0JVN.F0JVN.BEZSANWIQ.FWIQ.BEKUKEGOEVFSIFB1.SGFB1.FFARMEXFOEXF.TODP81.SGDP81.FDP81.BEDFFNCLNEXXA1.SGXXA1.MUXXA1.FXXA1.BEDMTKAPREACLS